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EFFECT OF PATIENT EDUCATION AND SUPERVISED
EXERCISE IN PATIENTS WITH HIP OSTEOARTHRITIS.
A RANDOMIZED CLINICAL TRIAL
L. Fernandes1, K. Storheim1, L. Nordsletten2, M. Risberg1
1NAR, Orthopaedic Ctr., Oslo Univ. Hosp., Ullevaal, Oslo, Norway;
2Orthopaedic Ctr., Oslo Univ. Hosp., Ullevaal, Oslo, Norway
Purpose: The purpose of the study was to evaluate the effect of
a supervised exercise program in addition to patient education for
patients with hip osteoarthritis.
Methods: One hundred and nine patients were included and
received three sessions of patient education. After completing
the patient education the 109 patients were randomized into 1)
follow the recommendations of self-management given during the
patient education (CG), or 2) follow the recommendations and,
in addition, a supervised exercise program (EG). The intervention
period lasted for 14 weeks. The patients were followed-up at
post-intervention (FU0), six months post-intervention (FU6), and
one year post-intervention (FU12). The main outcome was the
WOMAC VA3.1, and secondary outcomes were the 36-item Short-
Form health related quality of life questionnaire (SF-36v2), the
modiﬁed Physical Activity Scale for the Elderly (PASE) and the
self-efﬁcacy for pain. Linear mixed models analyses were used
for between group differences over time, and standardized mean
difference for the calculation of effect sizes.
Results: WOMAC physical function showed a signiﬁcant improved
score for the EG compared to the CG (p=0.047, CI 0.6-11.0) over
the follow-up period. No signiﬁcant differences between groups
over the follow-up period were seen for WOMAC pain or stiffness
subscales. Within-group analysis for the EG showed signiﬁcantly
improved WOMAC pain from baseline to FU0 (p=0.025, CI 0.7-
9.7), FU6 (p=0.004, CI 2.5-12.5), and FU12 (p=0.021, CI 0.8-10.1).
There were no signiﬁcant changes over time for the CG. The effect
sizes for the EG compared to the CG ranged from 0.26-0.35,
0.16-0.46, and 0.48-0.58 for pain, stiffness and physical function,
respectively, over the follow-up period. The secondary outcome,
SF-36 bodily pain, showed signiﬁcantly improved score (p=0.009,
CI 2.2-15.5) for the EG over the follow-up period. No signiﬁcant
differences between groups were seen in any of the other SF-36
sub-scales, in activity level (PASE) or in self-efﬁcacy for pain over
the follow-up period.
Conclusions: Physical function (WOMAC) and bodily pain (SF-
36) was signiﬁcantly improved for the EG compared to the CG
over the 1 year follow-up period, but there were no signiﬁcant
differences between the two groups for other WOMAC or SF-36
sub-scales, physical activity level or self-efﬁcacy for pain. There
was a small to moderate effect size for pain, stiffness, and physical
function for the EG compared to the CG.
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TREATMENT OF CARTILAGE DEFECTS IN THE KNEE
USING ALGINATE BEADS CONTAINING HUMAN MATURE
ALLOGENIC CHONDROCYTES: A 2-YEAR FOLLOW-UP
A.A. Dhollander, K.F. Almqvist, P.C. Verdonk, R. Forsyth,
R. Verdonk, G. Verbruggen
Ghent Univ., Ghent, Belgium
Purpose: To determine whether the implantation of alginate beads
containing human mature allogenic chondrocytes is feasible and
safe for the treatment of symptomatic cartilage defects in the knee.
Methods: A biodegradable, alginate-based biocompatible scaf-
fold containing human mature allogenic chondrocytes was used
for the treatment of chondral and osteochondral lesions in the
knee. Twenty-one patients were clinically prospectively evaluated
with use of the Western Ontario and McMaster Universities Os-
teoarthritis Index (WOMAC) and a Visual Analogue Scale (VAS)
for pain preoperatively and at 3, 6, 9, 12, 18 and 24 months of
follow-up. Of the 21 patients, 13 had consented to the taking of
a biopsy for investigative purposes from the area of implantation
at 12 months of follow-up, allowing histological assessment of the
repair tissue.
Results: A statistically signiﬁcant clinical improvement became
apparent after 6 months and patients improved during the 24
months of follow-up. Adverse reactions to the alginate/ﬁbrin matrix
seeded with the allogenic cartilage cells were not observed. Histo-
logical analysis of the biopsy specimens rated the repair tissue as
hyaline-like in 15.3 %, as mixed tissue in 46.2 %, as ﬁbrocartilage
in 30.8% and as ﬁbrous in 7.7%.
Conclusions: The results of this short term pilot study show that
the alginate-based scaffold containing human mature allogenic
chondrocytes is feasible and safe for the treatment of symptomatic
cartilage defects of the knee. The described technique provides
clinical and histological outcomes equal but not superior to those
of other cartilage repair techniques.
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THE EFFECTIVENESS OF GLUCOSAMINE SULFATE ON
CHRONIC LOW BACK PAIN WITH DEGENERATIVE
CHANGES. A RANDOMIZED TRIAL.
P. Wilkens Jr., K. Storheim, O. Grundnes, C. Hellum, I. Scheel
Ulleval Univ. Hosp., Oslo, Norway
Purpose: The aim of this trial is to test whether glucosamine
sulfate (GS) can reduce pain and discomfort in patients with
chronic low back pain LBP) and MRI-conﬁrmed degenerative
changes. Systematic reviews have reported potential mild effects
of glucosamine on knee osteoarthritis (OA), although the scientiﬁc
quality has been criticized. Though a clear relationship between
LBP and lumbar degenerative changes has not been found, GS
is increasingly being used in treatment. We have been unable to
identify any high quality trials on the effect of GS on chronic LBP.
A study of the effect of GS on chronic LBP is therefore needed.
Methods: The study is a randomized, double-blind, placebo-
controlled trial. Patients were recruited through primary health per-
sonnel and a single newspaper advert. Inclusion criteria: primary
complaint of chronic LBP (more than 6 months), ﬁndings of lumbar
degeneration seen on lumbar MRI (e.g. Modic changes, reduced
disc height etc), >25 years, able to speak and read Norwegian and
written informed consent. Exclusion criteria: symptomatic prolapse
and spinal stenosis, previous lumbar fracture or surgery, preg-
nancy, breastfeeding, seafood allergy or other disorders (physical
and/or psychological) known to inﬂuence their LBP. Interventions:
Patients were randomized (concealed and computer-generated)
to receive 1500mg GS (from Pharma Nord) daily or placebo. Out-
comes were measured 6, 12 and 24 weeks. Primary outcome: A 3
point difference in reduction between glucosamine- and placebo-
group measured with the Roland Morris Disability Questionnaire
(RMDQ). RMDQ is a self-reported measurement of pain and dis-
ability related to LBP. The properties of RMDQ have been studied
extensively. Secondary outcomes: Numerical Rating Scale (NRS)
for LBP and leg pain when active and inactive; low back stiff-
ness measured by NRS; health related quality of life (EQ-5D);
plasma glucose and cholesterol measured pre and post study
participation. Statistical analysis: Parametrical or non-parametrical
tests (e.g. indepentent t-tests, ANOVA analysis) will be used in
the main analysis depending on the data distribution. SPSS will
be used to conduct the analysis and followed the intention to treat
principle. The interim analysis reported here utilized repeated
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measurements (GLM) to compare the groups. The trial was ap-
proved by the regional ethics committee in Norway, Norwegian
Medicines Agency and the Norwegian Data Inspectorate. All pro-
cedures conformed to the Declaration of Helsinki. The trial was
registered at http://www.clinicaltrials.gov under the identiﬁer NCT
0040407. The trial was initiated by Ulleval University Hospital and
ﬁnanced by the Norwegian LBP organization and not producer
ﬁnanced.
Results: This is an interim analysis only. Mean age of the patients
(n=250) was 48,5 years. 48.4% were women. Lost to follow up at 6
months was 18 and equal in both groups. GS was not signiﬁcantly
better than placebo in reducing RMDQ score by 3 points. Repeated
measurements (GLM) demonstrated no difference between the
glucosamine- and the placebo-group. None of the secondary
outcomes (NPS, EQ-5D etc) demonstrated any difference between
the groups. RMDQ, NPS, LBP duration, race, age, sex, weight,
height, BMI, EQ-5D and HSCL-25 were similar in both groups at
baseline. No changes in fasting plasma glucose and cholesterol
levels were observed post trial participation in either treatment
arm. Adverse events were mild, rare and equally distributed among
the two groups.
Conclusions: Interim results show that daily intake of glu-
cosamine sulfate for 6 months was not effective in reducing low
back pain measured with RMDQ.
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THE EFFECT OF LATERAL-WEDGED INSOLES COMPARED
TO VALGUS BRACING IN THE TREATMENT OF MEDIAL
COMPARTMENTAL OSTEOARTHRITIS OF THE KNEE:
A PROSPECTIVE RANDOMIZED TRIAL
T.M. van Raaij1, M. Reijman1, R.W. Brouwer2,
S.M. Bierma-Zeinstra1, J.A. Verhaar1
1Erasmus MC, Rotterdam, Netherlands; 2Martini Hosp.,
Groningen, Netherlands
Purpose: The goal was to study the effect of a lateral-wedged
insole compared to valgus bracing in patients with symptomatic
medial compartmental knee osteoarthritis (OA).
Methods: Consecutive patients with symptomatic medial com-
partmental knee OA who visited the orthopaedic outpatient de-
partment of a university medical center were eligible for inclusion.
Patients with symptoms not related to medial compartmental OA,
younger than 35 years of age, an insufﬁcient command of the
Dutch language, or no varus malalignment were excluded. The
degree of knee alignment (hip-knee-ankle angle) was assessed
on a digitalized whole leg radiograph in standing position. After
written informed consent patients were randomly assigned to ei-
ther an intervention group comprising a shoe inserted leather sole
with a lateral-wedged cork elevation of 10 millimeters (6° wedge),
or to a control group comprising a commercially available valgus
knee brace. The allocation of treatment was concealed until after
the participants were included and baseline measurements were
executed. One assessor performed all baseline and 6 months
follow-up measurements.Primary outcome measure was change
in pain severity (VAS). Besides knee function scores (HSS, KSS,
WOMAC), percentage responders, varus alignment correction in
the frontal plane using the hip-knee-ankle angle, and compliance
to the intervention. Responders to the intervention were deﬁned
as having an improvement of ≥ 20% compared to the baseline
score for pain and function.
Results: Between January 2006 and September 2007, 91 con-
secutive patients were included and randomized (45 insole group;
46 brace group). Pain severity scores improved more in the insole
group compared with the bracing group for VAS (-.09; 95% CI:
-1.31; 1.13; effect size 0.04) and WOMAC pain score (.13; 95%CI:
-9.43; 9.18; effect size 0.004). Knee function was better for the
insole group for HSS score (1.69; 95% CI: -3.17; 6.55, effect size
0.16), KSS score (5.47; 95% CI: -12.48; 1.53, effect size 0.34),
and WOMAC function score (1.43; 95% CI: -9.39; 6.53, effect
size 0.07). There were no signiﬁcant differences in percentages
of responders between the insole and the brace groups (27% vs
25%, respectively).Both intervention had no impact on the varus
malalignment. At 6 months 71% of patients in the insole group
complied with the intervention, which was signiﬁcantly (p = 0.015)
higher compared to 45% for the brace group.
Conclusions: We found no differences in effectiveness of both a
6° lateral-wedged leather shoe inlay and a commercially available
valgus brace in the treatment of patients with symptomatic medial
OA of the knee joint after 6 months. According to the OMERACT-
OARSI set of responder criteria for clinical trials in OA, however,
only one fourth of all patients beneﬁted from either the insole or
brace intervention.
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A RANDOMIZED, PARALLEL GROUP, DOUBLE BLIND,
PLACEBO AND NAPROXEN CONTROLLED, MULTICENTER
PHASE 3 STUDY OF NAPROXCINOD IN SUBJECTS WITH
OSTEOARTHRITIS OF THE KNEE: EFFICACY RESULTS
FOLLOWING 13-WEEK TREATMENT
C.E. Marrero1, C. Tuten2, T. Shamim3, V. Awasty4, J. Agaiby5,
D. Hassman6, J. Sutphen7, H. Frayssinet8, B. Duquesroix8
1Deep South Clinical Res., Nederland, TX; 2Clinical Ctr. of
Asheville, Asheville, NC; 3Heartland Clinical Res., Omaha, NE;
4R&R Res., Marion, OH; 5Clinical Investigation Specialist, Inc,
Gurnee, IL; 6Comprehensive Clinical Res., Berlin, NJ; 7NicOx,
Warren, NJ; 8NicOx, Sophia Antipolis, France
Purpose: Naproxcinod is a Cyclooxygenase Inhibiting Nitric Ox-
ide Donator (CINOD) under development for the relief of signs
and symptoms of OA. Naproxcinod exerts its activity through its
two primary metabolites: naproxen and the NO donating moiety.
In previous clinical trials, naproxcinod has shown similar anti-
inﬂammatory and analgesic efﬁcacy to conventional NSAIDs, and
an improved BP safety and tolerability proﬁle, likely due to its NO
donation.
The primary objective of the study was to show that naproxcinod
375 mg bid and 750 mg bid were superior to placebo in relieving
signs and symptoms in subjects with OA of the knee after 13
weeks of treatment.
Methods: In this placebo 13-week and naproxen 26-week con-
trolled study, men and women 40+ years old with a diagnosis
of primary OA of the knee meeting ACR criteria and experienc-
ing a ﬂare of pain at baseline after discontinuation of previous
anti-inﬂammatory or acetaminophen treatments were randomized
(1:1:1:1) to either naproxcinod 375 mg or 750 mg bid, naproxen
500 mg bid or placebo bid. The three co-primary efﬁcacy variables
were the mean change from Baseline at Week 13 in WOMAC™
pain and function subscale scores and subject’s global assess-
ment of disease status. The superiority analysis of naproxcinod
over placebo was the primary efﬁcacy analysis.
The analysis of each primary efﬁcacy variable was based on
an analysis of covariance (ANCOVA) with treatment group as
factor, and baseline value as covariate. The primary efﬁcacy
analysis was performed using the Intent-to-Treat (ITT) population
(all randomized subjects) and was performed on as-randomized
basis.
Results: A total of 1011 subjects from 129 US centers were
included in the ITT population. 71.0% of subjects were female,
78.9% were Caucasian. The mean age was 59.8 years and mean
BMI 33.8 kg/m2. A total of 766 (75.8%) subjects completed the 13
week study period.
Both doses of naproxcinod (375 mg bid and 750 mg bid) demon-
